European Journal of Cancer

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Volume 64, Issue 5, Pages (November 2013)
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.
Breast Cancer Advocacy across Europe through the work and development of EUROPA DONNA, the European Breast Cancer Coalition  M. Buchanan, S. Kyriakides,
European Journal of Cancer
Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit  Pim J. van Leeuwen, David Connolly, Anna.
Volume 72, Issue 4, Pages (October 2017)
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
The PSA Era is not Over for Prostate Cancer
Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D
Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.
Volume 195, Issue 5, Pages (May 2016)
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 52, Issue 5, Pages (November 2007)
Prostate Cancer 2008: Challenges in Diagnosis and Management
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Jaden D. Evans, MD, Krishan R
Volume 73, Issue 5, Pages (May 2018)
Volume 74, Issue 2, Pages (August 2018)
Volume 53, Issue 5, Pages (May 2008)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Volume 72, Issue 4, Pages (October 2017)
Volume 71, Issue 5, Pages (May 2017)
Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri 
Volume 65, Issue 5, Pages (May 2014)
Volume 64, Issue 5, Pages (November 2013)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Testicular Cancer (C62): 2008 Estimates
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
International Journal of Surgery
Volume 62, Issue 1, Pages (July 2012)
Volume 67, Issue 6, Pages (June 2015)
Pain, Fatigue, and Sleep Disturbances in Oncology Outpatients Receiving Radiation Therapy for Bone Metastasis  Christine Miaskowski, RN, PhD, FAAN, Kathryn.
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Volume 64, Issue 6, Pages (December 2013)
The PSA Era is not Over for Prostate Cancer
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer  I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 74, Issue 2, Pages (August 2018)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Volume 50, Issue 5, Pages (November 2006)
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure 
The Importance of Testosterone Control in Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Volume 58, Issue 3, Pages (March 2013)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer 2008: Challenges in Diagnosis and Management
Support Your Specialty
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Manfred Wirth, Peter Iversen, David McLeod, William See 
European Lung Cancer Conference (ELCC) 2016 Organisation
Predicting Place of Death of Elderly Cancer Patients Followed by a Palliative Care Unit  Anna Maria Izquierdo-Porrera, MD, Jordi Trelis-Navarro, MD, Xavier.
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Does PSA Testing Influence the Natural History of Prostate Cancer?
Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life  Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith.
Presentation transcript:

European Journal of Cancer Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy  John O. Prior, Silke Gillessen, Manfred Wirth, William Dale, Matti Aapro, Wim J.G. Oyen  European Journal of Cancer  Volume 77, Pages 127-139 (May 2017) DOI: 10.1016/j.ejca.2017.01.030 Copyright © 2017 The Author(s) Terms and Conditions

Fig. 1 (A) Incidence and (B) mortality of the three most frequently encountered cancers in Europe in men and women according to age (Data from [http://globocan.iarc.fr GLOBOCAN 2012, last accessed on September 2014, 21], IARC®). European Journal of Cancer 2017 77, 127-139DOI: (10.1016/j.ejca.2017.01.030) Copyright © 2017 The Author(s) Terms and Conditions

Fig. 2 A 69-year old patient with biochemical relapse from prostate cancer (Gleason 7, PSA3 ng/ml) showing a single site of bone metastasis on the right ischium with 18F-choline PET not visible by bone scintigraphy. The patient received isolated radiation therapy and the PSA decreased to <0.05 ng/ml). He has been relapse-free for 24 months. European Journal of Cancer 2017 77, 127-139DOI: (10.1016/j.ejca.2017.01.030) Copyright © 2017 The Author(s) Terms and Conditions

Fig. 3 Example of bone scintigraphic response in a 72-year old patient with metastatic castration-resistant prostate cancer and multiple bone metastases (A) in the skull, right hemi-jaw, left shoulder, ribs, thoracic and lumbar spine and (B) after six courses of 223Ra over 6°months. European Journal of Cancer 2017 77, 127-139DOI: (10.1016/j.ejca.2017.01.030) Copyright © 2017 The Author(s) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.